financetom
Business
financetom
/
Business
/
Texmaco promoters to infuse up to Rs 200cr capital
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Texmaco promoters to infuse up to Rs 200cr capital
Sep 9, 2020 8:04 AM

Texmaco Rail and Engineering Ltd has said it will not proceed with the proposed rights issue amid a slowdown in the economy, and its promoters will infuse equity capital up to Rs 200 crore to meet fund requirement of the company. Last year, the board had approved the rights issue to ensure adequate resource availability for the firm.

”…regard to the urgency of the fund requirements of the company, the board has approved the issuance of equity shares of the company by way of the preferential issue to the promoters for an amount not exceeding Rs 200 crore,” a company statement said. After reviewing its earlier decision, the board has decided not to proceed with the rights offer amid an overall slowdown in the economy and decline in stock price.

The company posted Rs 27 crore loss in the first quarter of the current fiscal due to the disruptions caused by the COVID-19 crisis. ”The overall impact of COVID-19 on the country is still severe… the silver lining is the privatisation of railway services to boost rail infrastructure. This would lead to the generation of new opportunities,” the company said on Tuesday.

The consolidated order book of the company is at Rs 4,200 crore, it said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says
Vera Therapeutics Poised for Strong Upside on 'Rare' Autoimmune Drug Opportunity, BofA Says
Oct 16, 2025
12:49 PM EDT, 10/16/2025 (MT Newswires) -- Vera Therapeutics ( VERA ) offers a compelling entry point ahead of its anticipated mid-2026 commercial launch of atacicept, which could transform the treatment of immunoglobulin A nephropathy, BofA Securities said in a note Thursday. BofA said atacicept's launch could exceed consensus estimates by 15% to 20% and ease competitive risk concerns as...
InterRent Real Estate Investment Trust Announces Monthly Distribution for October
InterRent Real Estate Investment Trust Announces Monthly Distribution for October
Oct 16, 2025
12:47 PM EDT, 10/16/2025 (MT Newswires) -- InterRent Real Estate Investment Trust (IIP-UN.TO) on Thursday declared a monthly distribution for October of $0.033075 per unit, equivalent to an annualized rate of $0.3969 per unit. The payment, unchanged from last month, will be made on or about Nov.17, to unitholders of record as of Oct.31. ...
Sector Update: Consumer
Sector Update: Consumer
Oct 16, 2025
01:23 PM EDT, 10/16/2025 (MT Newswires) -- Consumer stocks declined Thursday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.4% and the Consumer Discretionary Select Sector SPDR Fund (XLY) shedding 0.6%. In corporate news, General Motors ( GM ) and its joint venture partner, South Korea's Posco Future M, have paused the second phase of a cathode...
Why Is BTQ Technologies Stock Up Today?
Why Is BTQ Technologies Stock Up Today?
Oct 16, 2025
Shares of BTQ Technologies Corp. ( BTQ ) are rising Thursday after the company announced that it reached a significant technological milestone. BTQ shares are climbing with conviction. Get the complete analysis here. What To Know: BTQ Technologies ( BTQ ) announced the first successful demonstration of a quantum-resistant Bitcoin (CRYPTO: BTC) implementation using National Institute of Standards and Technology (NIST)-standardized post-quantum cryptography....
Copyright 2023-2026 - www.financetom.com All Rights Reserved